Takeda gets China's approval for $62 billion Shire purchase

2
© Reuters. FILE PHOTO: Shire branding is seen outside their offices in Dublin© Reuters. FILE PHOTO: Shire branding is seen outside their offices in Dublin

(Reuters) – Takeda Pharmaceutical Co Ltd said on Friday China approved its purchase of Shire Plc (LON:), the latest regulator to clear the $62 billion deal and bring the Japanese group closer to becoming a global top 10 drugmaker.

The acquisition, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from U.S. and Brazilian regulators and awaits approval from Japan and the European Union.

Takeda expects the deal to close in the first half of 2019.

Its shares ended 0.7 percent higher ahead of the announcement. The benchmark closed up 1.2 percent.

Takeda’s stock is down 15 percent since the company first said it was considering a bid for Shire, with investors concerned about the heavy debt burden the deal will impose on the drugmaker.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

2 COMMENTS

Comments are closed.